13 November 2023
Sidley Represents CKD Pharma in US$1.3 Billion Out-license of Its Proprietary Therapeutic to Novartis
Advising firms
Deal team
10 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Joshua Hofheimer Lead | Sidley | Not stated | Life Sciences Transactions | Century City |
| Jean Qiu Lead | Sidley | Not stated | Life Sciences Transactions | Shanghai |
| Sabrina Glavota Lead | Sidley | Not stated | Life Sciences Transactions | Century City |
| Sue Wang | Sidley | Not stated | IP Litigation | San Francisco |
| Scott Kaplan | Sidley | Not stated | Food Drug and Medical Device | Washington, D.C. |
| Kelly Cho | Sidley | Not stated | Food Drug and Medical Device | Washington, D.C. |
| Matt Clemente | Sidley | Not stated | Restructuring | Chicago |
| James W. Lowe | Sidley | Not stated | Antitrust and Competition | Washington, D.C. |
| Edward Sharon | Sidley | Not stated | Antitrust and Competition | Washington, D.C. |
| Miriam Carroll Silvestri | Sidley | Not stated | Antitrust and Competition | Washington, D.C. |
Stated terms
- Stated value
- USD 1.30bn (US$1.3 billion)
- What the figure measures
- Total transaction value
- Client
- Chong Kun Dang Corp. (CKD)Sell-side
- Counterparties
- Novartis AG (Buy-side)